Pharmaceutical Products Sample Clauses

Pharmaceutical Products. A change to 30.01-30.05 heading totalled 30.01 to 30.05 from any other heading; or It does not require a change in tariff classification heading to totalled 30.01 to 30.05, complying with a regional value content requirement according to Article 4.2. A change to 3006.10-3006.40 subheading 3006.10 to 3006.40 from any other heading; or there is a change in tariff classification at the subheading 3006.10 to 3006.40, complying with a regional value content requirement according to Article 4.2. 3006.50 provided that qualifies as originating in accordance with article 4.11. a change to 3006.60-3006.91 subheading 3006.60 to 3006.70 from any other heading; or there is a change in tariff classification at the subheading 3006.60 to 3006.91, complying with a regional value content requirement according to Article 4.2. It does not require 3006.92 tariff classification change to subheading 3006.80 provided that waste and scrap are wholly obtained or produced entirely in the territory of a Party as defined in article 4.26. Article 31. Fertilizers 31.01-31.05 heading to a change to 31.02 31.05 from any other heading; or It does not require a change in tariff classification heading to 31.02 to 31.05, complying with a regional value content requirement according to Article 4.2.
Pharmaceutical Products. (a) Schedule 4.24(a) lists each product manufactured, licensed, distributed or sold by the Company (collectively, the "Products"). The Company does not manufacture any Product.
Pharmaceutical Products. Solid, orally administered medications will be provided in true unit-dose blister cards, in which medications eligible for credit will have each individual bubble of the blister card labeled with the medication’s name and strength, lot number, NDC, manufacturer’s name, and expiration date. Prescription labels are customizable with Facility-specific information and are barcoded to allow for inventory management as well as quality assurance during med pass. Each prescription label will contain a two-part peel-off tab to allow easy refill processing. Maintenance medications will be dispensed in a 30-day supply unless otherwise requested. Oral solid patient specific medications and legend oral-solid stock will be dispensed in 30-count blister cards with one unit per bubble. Vendor will dispense acute medications in quantities requested by the Member depending on the frequency of the dosing and the needs of the Member. OTCs can be ordered by the Member directly from their MMCAP wholesaler or from the Vendor. If packaging other than blister cards is required, a new rate will be negotiated and documented in Attachment A. Patient medication information monographs are available for correctional Member Facilities 24/7/365 and can be printed at Facility level from Vendor’s web-based Sapphire eMAR Program or via their free web- based Online Reporting Program (ORP). Institutional facilities may be granted access to the ORP upon request. Vendor provides non-oral solids and products such as ear drops, liquids, creams, or ointments in the original manufacturer container or shall repackage in alternate containers if requested, with no packaging fee. Vendor’s blister cards will be true unit-dose packaging for medications eligible for reclamation from, and credit to correctional facilities. While the label itself contains detailed information, the back of each pill bubble in the blister card is labeled with the medication name and strength, lot number, expiration date, and manufacturer ID. Only true unit-dose packaging allows for credit on returned medications that are being reclaimed. This will apply to medications eligible for the Credit Returns Policy, described in Article 2.6.
Pharmaceutical Products. “Pharmaceutical Products” shall mean all biological and drug candidates, compounds or other pharmaceutical products.
Pharmaceutical Products. (a) Schedule 4.25(a) lists each product currently developed, manufactured, licensed, distributed or sold by the Company or any Company Subsidiary (collectively, the "Products"). Each Product manufactured by the Company or any Company Subsidiary has been manufactured in accordance with (i) the product registration applicable to such Product, and (ii) the specifications under which the Product is normally and has normally been manufactured.
Pharmaceutical Products. (a) King and King-Nevada represent and warrant that they have delivered to Mallinckrodt certain information or given Mallinckrodt access to all existing information regarding each of the Current Products (along with a description of its container/closure system) currently manufactured, marketed, sold or licensed by King, King-Nevada or their affiliates. The Current Products and all other products currently manufactured, sold or licensed by King, King-Nevada or their affiliates are referred to collectively as the "Pharmaceutical Products".
Pharmaceutical Products. 3001.10-3006.60 A change to any one of subheading 3001.10 through 3006.60 from within that subheading or any other subheading, including another subheading within that group. Chapter 31 Fertilizers 3101.00-3105.90 A change to any one of subheading 3101.00 through 3105.90 from within that subheading or any other subheading, including another subheading within that group.
Pharmaceutical Products. The Company has, since the inception of the Company, not sold any products.
Pharmaceutical Products. US $1,000,000 payable upon first IND approval; US $1,000,000 payable upon positive outcome of Phase II trial in first indication; US $2,000,000 payable upon NDA approval